 | • レポートコード：QYR2104Z3994 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、骨髄異形成症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アルキル化剤、細胞毒性抗生物質、トポイソメラーゼ阻害剤、その他）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・骨髄異形成症候群の市場動向 ・企業の競争状況、市場シェア ・骨髄異形成症候群の種類別市場規模（アルキル化剤、細胞毒性抗生物質、トポイソメラーゼ阻害剤、その他） ・骨髄異形成症候群の用途別市場規模（病院、診療所） ・骨髄異形成症候群の北米市場規模2016-2027（アメリカ、カナダ） ・骨髄異形成症候群のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・骨髄異形成症候群のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・骨髄異形成症候群の中南米市場規模2016-2027（メキシコ、ブラジル） ・骨髄異形成症候群の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Celgene、Novartis、Otsuka、Actinium Pharmaceuticals、Acceleron Pharma、Bellicum Pharmaceuticals、Cornerstone Pharmaceuticals、CTI BioPharma、Onconova Therapeutics、Strategia Therapeutics、KaloBios Pharmaceuticals、Kiadis Pharma、Mirati Therapeutics、Astex、Celator Pharmaceuticals、Eli-lilly、Sunesis Pharmaceuticals、Targazyme、Gamida Cell、GlaxoSmithKline、Sumitomo Dainippon Pharma、TetraLogic Pharmaceuticals） ・結論 |
Market Analysis and Insights: Global Myelodysplastic Syndrome Market
The global Myelodysplastic Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myelodysplastic Syndrome market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myelodysplastic Syndrome market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myelodysplastic Syndrome market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myelodysplastic Syndrome market.
Global Myelodysplastic Syndrome Scope and Market Size
Myelodysplastic Syndrome market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Alkylating Agents
Cytotoxic Antibiotics
Topoisomerase Inhibitors
Others
Segment by Application
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Actinium Pharmaceuticals
Acceleron Pharma
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli-lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
GlaxoSmithKline
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Alkylating Agents
1.2.3 Cytotoxic Antibiotics
1.2.4 Topoisomerase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome Market Perspective (2016-2027)
2.2 Myelodysplastic Syndrome Growth Trends by Regions
2.2.1 Myelodysplastic Syndrome Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myelodysplastic Syndrome Historic Market Share by Regions (2016-2021)
2.2.3 Myelodysplastic Syndrome Forecasted Market Size by Regions (2022-2027)
2.3 Myelodysplastic Syndrome Industry Dynamic
2.3.1 Myelodysplastic Syndrome Market Trends
2.3.2 Myelodysplastic Syndrome Market Drivers
2.3.3 Myelodysplastic Syndrome Market Challenges
2.3.4 Myelodysplastic Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome Players by Revenue (2016-2021)
3.1.2 Global Myelodysplastic Syndrome Revenue Market Share by Players (2016-2021)
3.2 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome Revenue
3.4 Global Myelodysplastic Syndrome Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2020
3.5 Myelodysplastic Syndrome Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome Historic Market Size by Type (2016-2021)
4.2 Global Myelodysplastic Syndrome Forecasted Market Size by Type (2022-2027)
5 Myelodysplastic Syndrome Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome Historic Market Size by Application (2016-2021)
5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Myelodysplastic Syndrome Market Size (2016-2027)
6.2 North America Myelodysplastic Syndrome Market Size by Type
6.2.1 North America Myelodysplastic Syndrome Market Size by Type (2016-2021)
6.2.2 North America Myelodysplastic Syndrome Market Size by Type (2022-2027)
6.2.3 North America Myelodysplastic Syndrome Market Size by Type (2016-2027)
6.3 North America Myelodysplastic Syndrome Market Size by Application
6.3.1 North America Myelodysplastic Syndrome Market Size by Application (2016-2021)
6.3.2 North America Myelodysplastic Syndrome Market Size by Application (2022-2027)
6.3.3 North America Myelodysplastic Syndrome Market Size by Application (2016-2027)
6.4 North America Myelodysplastic Syndrome Market Size by Country
6.4.1 North America Myelodysplastic Syndrome Market Size by Country (2016-2021)
6.4.2 North America Myelodysplastic Syndrome Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome Market Size (2016-2027)
7.2 Europe Myelodysplastic Syndrome Market Size by Type
7.2.1 Europe Myelodysplastic Syndrome Market Size by Type (2016-2021)
7.2.2 Europe Myelodysplastic Syndrome Market Size by Type (2022-2027)
7.2.3 Europe Myelodysplastic Syndrome Market Size by Type (2016-2027)
7.3 Europe Myelodysplastic Syndrome Market Size by Application
7.3.1 Europe Myelodysplastic Syndrome Market Size by Application (2016-2021)
7.3.2 Europe Myelodysplastic Syndrome Market Size by Application (2022-2027)
7.3.3 Europe Myelodysplastic Syndrome Market Size by Application (2016-2027)
7.4 Europe Myelodysplastic Syndrome Market Size by Country
7.4.1 Europe Myelodysplastic Syndrome Market Size by Country (2016-2021)
7.4.2 Europe Myelodysplastic Syndrome Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome Market Size (2016-2027)
8.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Type
8.2.1 Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2016-2027)
8.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Application
8.3.1 Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2016-2027)
8.4 Asia-Pacific Myelodysplastic Syndrome Market Size by Region
8.4.1 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome Market Size (2016-2027)
9.2 Latin America Myelodysplastic Syndrome Market Size by Type
9.2.1 Latin America Myelodysplastic Syndrome Market Size by Type (2016-2021)
9.2.2 Latin America Myelodysplastic Syndrome Market Size by Type (2022-2027)
9.2.3 Latin America Myelodysplastic Syndrome Market Size by Type (2016-2027)
9.3 Latin America Myelodysplastic Syndrome Market Size by Application
9.3.1 Latin America Myelodysplastic Syndrome Market Size by Application (2016-2021)
9.3.2 Latin America Myelodysplastic Syndrome Market Size by Application (2022-2027)
9.3.3 Latin America Myelodysplastic Syndrome Market Size by Application (2016-2027)
9.4 Latin America Myelodysplastic Syndrome Market Size by Country
9.4.1 Latin America Myelodysplastic Syndrome Market Size by Country (2016-2021)
9.4.2 Latin America Myelodysplastic Syndrome Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome Market Size (2016-2027)
10.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Type
10.2.1 Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2016-2027)
10.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Application
10.3.1 Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2016-2027)
10.4 Middle East & Africa Myelodysplastic Syndrome Market Size by Country
10.4.1 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Myelodysplastic Syndrome Introduction
11.1.4 Celgene Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.1.5 Celgene Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Myelodysplastic Syndrome Introduction
11.2.4 Novartis Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Details
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Myelodysplastic Syndrome Introduction
11.3.4 Otsuka Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.3.5 Otsuka Recent Development
11.4 Actinium Pharmaceuticals
11.4.1 Actinium Pharmaceuticals Company Details
11.4.2 Actinium Pharmaceuticals Business Overview
11.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Introduction
11.4.4 Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.4.5 Actinium Pharmaceuticals Recent Development
11.5 Acceleron Pharma
11.5.1 Acceleron Pharma Company Details
11.5.2 Acceleron Pharma Business Overview
11.5.3 Acceleron Pharma Myelodysplastic Syndrome Introduction
11.5.4 Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.5.5 Acceleron Pharma Recent Development
11.6 Bellicum Pharmaceuticals
11.6.1 Bellicum Pharmaceuticals Company Details
11.6.2 Bellicum Pharmaceuticals Business Overview
11.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Introduction
11.6.4 Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.6.5 Bellicum Pharmaceuticals Recent Development
11.7 Cornerstone Pharmaceuticals
11.7.1 Cornerstone Pharmaceuticals Company Details
11.7.2 Cornerstone Pharmaceuticals Business Overview
11.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Introduction
11.7.4 Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.7.5 Cornerstone Pharmaceuticals Recent Development
11.8 CTI BioPharma
11.8.1 CTI BioPharma Company Details
11.8.2 CTI BioPharma Business Overview
11.8.3 CTI BioPharma Myelodysplastic Syndrome Introduction
11.8.4 CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.8.5 CTI BioPharma Recent Development
11.9 Onconova Therapeutics
11.9.1 Onconova Therapeutics Company Details
11.9.2 Onconova Therapeutics Business Overview
11.9.3 Onconova Therapeutics Myelodysplastic Syndrome Introduction
11.9.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.9.5 Onconova Therapeutics Recent Development
11.10 Strategia Therapeutics
11.10.1 Strategia Therapeutics Company Details
11.10.2 Strategia Therapeutics Business Overview
11.10.3 Strategia Therapeutics Myelodysplastic Syndrome Introduction
11.10.4 Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.10.5 Strategia Therapeutics Recent Development
11.11 KaloBios Pharmaceuticals
11.11.1 KaloBios Pharmaceuticals Company Details
11.11.2 KaloBios Pharmaceuticals Business Overview
11.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Introduction
11.11.4 KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.11.5 KaloBios Pharmaceuticals Recent Development
11.12 Kiadis Pharma
11.12.1 Kiadis Pharma Company Details
11.12.2 Kiadis Pharma Business Overview
11.12.3 Kiadis Pharma Myelodysplastic Syndrome Introduction
11.12.4 Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.12.5 Kiadis Pharma Recent Development
11.13 Mirati Therapeutics
11.13.1 Mirati Therapeutics Company Details
11.13.2 Mirati Therapeutics Business Overview
11.13.3 Mirati Therapeutics Myelodysplastic Syndrome Introduction
11.13.4 Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.13.5 Mirati Therapeutics Recent Development
11.14 Astex
11.14.1 Astex Company Details
11.14.2 Astex Business Overview
11.14.3 Astex Myelodysplastic Syndrome Introduction
11.14.4 Astex Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.14.5 Astex Recent Development
11.15 Celator Pharmaceuticals
11.15.1 Celator Pharmaceuticals Company Details
11.15.2 Celator Pharmaceuticals Business Overview
11.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Introduction
11.15.4 Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.15.5 Celator Pharmaceuticals Recent Development
11.16 Eli-lilly
11.16.1 Eli-lilly Company Details
11.16.2 Eli-lilly Business Overview
11.16.3 Eli-lilly Myelodysplastic Syndrome Introduction
11.16.4 Eli-lilly Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.16.5 Eli-lilly Recent Development
11.17 Sunesis Pharmaceuticals
11.17.1 Sunesis Pharmaceuticals Company Details
11.17.2 Sunesis Pharmaceuticals Business Overview
11.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Introduction
11.17.4 Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.17.5 Sunesis Pharmaceuticals Recent Development
11.18 Targazyme
11.18.1 Targazyme Company Details
11.18.2 Targazyme Business Overview
11.18.3 Targazyme Myelodysplastic Syndrome Introduction
11.18.4 Targazyme Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.18.5 Targazyme Recent Development
11.18 Gamida Cell
.1 Gamida Cell Company Details
.2 Gamida Cell Business Overview
.3 Gamida Cell Myelodysplastic Syndrome Introduction
.4 Gamida Cell Revenue in Myelodysplastic Syndrome Business (2016-2021)
.5 Gamida Cell Recent Development
11.20 GlaxoSmithKline
11.20.1 GlaxoSmithKline Company Details
11.20.2 GlaxoSmithKline Business Overview
11.20.3 GlaxoSmithKline Myelodysplastic Syndrome Introduction
11.20.4 GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.20.5 GlaxoSmithKline Recent Development
11.21 Sumitomo Dainippon Pharma
11.21.1 Sumitomo Dainippon Pharma Company Details
11.21.2 Sumitomo Dainippon Pharma Business Overview
11.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Introduction
11.21.4 Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.21.5 Sumitomo Dainippon Pharma Recent Development
11.22 TetraLogic Pharmaceuticals
11.22.1 TetraLogic Pharmaceuticals Company Details
11.22.2 TetraLogic Pharmaceuticals Business Overview
11.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Introduction
11.22.4 TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021)
11.22.5 TetraLogic Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Myelodysplastic Syndrome Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Alkylating Agents
Table 3. Key Players of Cytotoxic Antibiotics
Table 4. Key Players of Topoisomerase Inhibitors
Table 5. Key Players of Others
Table 6. Global Myelodysplastic Syndrome Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myelodysplastic Syndrome Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Myelodysplastic Syndrome Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Myelodysplastic Syndrome Market Share by Regions (2016-2021)
Table 10. Global Myelodysplastic Syndrome Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Myelodysplastic Syndrome Market Share by Regions (2022-2027)
Table 12. Myelodysplastic Syndrome Market Trends
Table 13. Myelodysplastic Syndrome Market Drivers
Table 14. Myelodysplastic Syndrome Market Challenges
Table 15. Myelodysplastic Syndrome Market Restraints
Table 16. Global Myelodysplastic Syndrome Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Myelodysplastic Syndrome Market Share by Players (2016-2021)
Table 18. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome as of 2020)
Table 19. Ranking of Global Top Myelodysplastic Syndrome Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Myelodysplastic Syndrome Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Myelodysplastic Syndrome Product Solution and Service
Table 23. Date of Enter into Myelodysplastic Syndrome Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Myelodysplastic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Myelodysplastic Syndrome Revenue Market Share by Type (2016-2021)
Table 27. Global Myelodysplastic Syndrome Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Myelodysplastic Syndrome Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Myelodysplastic Syndrome Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Myelodysplastic Syndrome Revenue Market Share by Application (2016-2021)
Table 31. Global Myelodysplastic Syndrome Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Myelodysplastic Syndrome Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Myelodysplastic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Myelodysplastic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Myelodysplastic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Myelodysplastic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Myelodysplastic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Myelodysplastic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Myelodysplastic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Myelodysplastic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Myelodysplastic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Myelodysplastic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Myelodysplastic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Myelodysplastic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Myelodysplastic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Myelodysplastic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Myelodysplastic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Myelodysplastic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Myelodysplastic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Myelodysplastic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 63. Celgene Company Details
Table 64. Celgene Business Overview
Table 65. Celgene Myelodysplastic Syndrome Product
Table 66. Celgene Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 67. Celgene Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Myelodysplastic Syndrome Product
Table 71. Novartis Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Otsuka Company Details
Table 74. Otsuka Business Overview
Table 75. Otsuka Myelodysplastic Syndrome Product
Table 76. Otsuka Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 77. Otsuka Recent Development
Table 78. Actinium Pharmaceuticals Company Details
Table 79. Actinium Pharmaceuticals Business Overview
Table 80. Actinium Pharmaceuticals Myelodysplastic Syndrome Product
Table 81. Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 82. Actinium Pharmaceuticals Recent Development
Table 83. Acceleron Pharma Company Details
Table 84. Acceleron Pharma Business Overview
Table 85. Acceleron Pharma Myelodysplastic Syndrome Product
Table 86. Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 87. Acceleron Pharma Recent Development
Table 88. Bellicum Pharmaceuticals Company Details
Table 89. Bellicum Pharmaceuticals Business Overview
Table 90. Bellicum Pharmaceuticals Myelodysplastic Syndrome Product
Table 91. Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 92. Bellicum Pharmaceuticals Recent Development
Table 93. Cornerstone Pharmaceuticals Company Details
Table 94. Cornerstone Pharmaceuticals Business Overview
Table 95. Cornerstone Pharmaceuticals Myelodysplastic Syndrome Product
Table 96. Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 97. Cornerstone Pharmaceuticals Recent Development
Table 98. CTI BioPharma Company Details
Table 99. CTI BioPharma Business Overview
Table 100. CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 101. CTI BioPharma Recent Development
Table 102. Onconova Therapeutics Company Details
Table 103. Onconova Therapeutics Business Overview
Table 104. Onconova Therapeutics Myelodysplastic Syndrome Product
Table 105. Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 106. Onconova Therapeutics Recent Development
Table 107. Strategia Therapeutics Company Details
Table 108. Strategia Therapeutics Business Overview
Table 109. Strategia Therapeutics Myelodysplastic Syndrome Product
Table 110. Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 111. Strategia Therapeutics Recent Development
Table 112. KaloBios Pharmaceuticals Company Details
Table 113. KaloBios Pharmaceuticals Business Overview
Table 114. KaloBios Pharmaceuticals Myelodysplastic Syndrome Product
Table 115. KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 116. KaloBios Pharmaceuticals Recent Development
Table 117. Kiadis Pharma Company Details
Table 118. Kiadis Pharma Business Overview
Table 119. Kiadis Pharma Myelodysplastic Syndrome Product
Table 120. Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 121. Kiadis Pharma Recent Development
Table 122. Mirati Therapeutics Company Details
Table 123. Mirati Therapeutics Business Overview
Table 124. Mirati Therapeutics Myelodysplastic Syndrome Product
Table 125. Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 126. Mirati Therapeutics Recent Development
Table 127. Astex Company Details
Table 128. Astex Business Overview
Table 129. Astex Myelodysplastic Syndrome Product
Table 130. Astex Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 131. Astex Recent Development
Table 132. Celator Pharmaceuticals Company Details
Table 133. Celator Pharmaceuticals Business Overview
Table 134. Celator Pharmaceuticals Myelodysplastic Syndrome Product
Table 135. Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 136. Celator Pharmaceuticals Recent Development
Table 137. Eli-lilly Company Details
Table 138. Eli-lilly Business Overview
Table 139. Eli-lilly Myelodysplastic Syndrome Product
Table 140. Eli-lilly Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 141. Eli-lilly Recent Development
Table 142. Sunesis Pharmaceuticals Company Details
Table 143. Sunesis Pharmaceuticals Business Overview
Table 144. Sunesis Pharmaceuticals Myelodysplastic Syndrome Product
Table 145. Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 146. Sunesis Pharmaceuticals Recent Development
Table 147. Targazyme Company Details
Table 148. Targazyme Business Overview
Table 149. Targazyme Myelodysplastic Syndrome Product
Table 150. Targazyme Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 151. Targazyme Recent Development
Table 152. Gamida Cell Company Details
Table 153. Gamida Cell Business Overview
Table 154. Gamida Cell Myelodysplastic Syndrome Product
Table 155. Gamida Cell Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 156. Gamida Cell Recent Development
Table 157. GlaxoSmithKline Company Details
Table 158. GlaxoSmithKline Business Overview
Table 159. GlaxoSmithKline Myelodysplastic Syndrome Product
Table 160. GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 161. GlaxoSmithKline Recent Development
Table 162. Sumitomo Dainippon Pharma Company Details
Table 163. Sumitomo Dainippon Pharma Business Overview
Table 164. Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product
Table 165. Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 166. Sumitomo Dainippon Pharma Recent Development
Table 167. TetraLogic Pharmaceuticals Company Details
Table 168. TetraLogic Pharmaceuticals Business Overview
Table 169. TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product
Table 170. TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2016-2021) & (US$ Million)
Table 171. TetraLogic Pharmaceuticals Recent Development
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome Market Share by Type: 2020 VS 2027
Figure 2. Alkylating Agents Features
Figure 3. Cytotoxic Antibiotics Features
Figure 4. Topoisomerase Inhibitors Features
Figure 5. Others Features
Figure 6. Global Myelodysplastic Syndrome Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Myelodysplastic Syndrome Report Years Considered
Figure 10. Global Myelodysplastic Syndrome Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Myelodysplastic Syndrome Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Myelodysplastic Syndrome Market Share by Regions: 2020 VS 2027
Figure 13. Global Myelodysplastic Syndrome Market Share by Regions (2022-2027)
Figure 14. Global Myelodysplastic Syndrome Market Share by Players in 2020
Figure 15. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome Revenue in 2020
Figure 17. Global Myelodysplastic Syndrome Revenue Market Share by Type (2016-2021)
Figure 18. Global Myelodysplastic Syndrome Revenue Market Share by Type (2022-2027)
Figure 19. North America Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Myelodysplastic Syndrome Market Share by Type (2016-2027)
Figure 21. North America Myelodysplastic Syndrome Market Share by Application (2016-2027)
Figure 22. North America Myelodysplastic Syndrome Market Share by Country (2016-2027)
Figure 23. United States Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myelodysplastic Syndrome Market Share by Type (2016-2027)
Figure 27. Europe Myelodysplastic Syndrome Market Share by Application (2016-2027)
Figure 28. Europe Myelodysplastic Syndrome Market Share by Country (2016-2027)
Figure 29. Germany Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myelodysplastic Syndrome Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Myelodysplastic Syndrome Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Myelodysplastic Syndrome Market Share by Region (2016-2027)
Figure 39. China Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myelodysplastic Syndrome Market Share by Type (2016-2027)
Figure 47. Latin America Myelodysplastic Syndrome Market Share by Application (2016-2027)
Figure 48. Latin America Myelodysplastic Syndrome Market Share by Country (2016-2027)
Figure 49. Mexico Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myelodysplastic Syndrome Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Myelodysplastic Syndrome Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Myelodysplastic Syndrome Market Share by Country (2016-2027)
Figure 55. Turkey Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Myelodysplastic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Celgene Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 59. Novartis Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 60. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 61. Actinium Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 62. Acceleron Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 63. Bellicum Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 64. Cornerstone Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 65. CTI BioPharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 66. Onconova Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 67. Strategia Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 68. KaloBios Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 69. Kiadis Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 70. Mirati Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 71. Astex Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 72. Celator Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 73. Eli-lilly Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 74. Sunesis Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 75. Targazyme Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 76. Gamida Cell Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 77. GlaxoSmithKline Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 78. Sumitomo Dainippon Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 79. TetraLogic Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2016-2021)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
世界の骨髄異形成症候群（MDS）治療薬市場 2021：企業別、地域別、種類・用途別 The Myelodysplastic Syndrome (MDS) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …- 世界の骨髄異形成症候群（MDS）治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Therapeutics Market The global Myelodysplastic Syndrome (MDS) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in …
- 世界の骨髄異形成症候群（MDS）治療市場 2021：企業別、地域別、種類・用途別 The Myelodysplastic Syndrome (MDS) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizati…
- 世界のゾリンジャー-エリソン症候群検査市場規模・現状・予測（2021年-2027年） Zollinger-Ellison syndrome is a rare condition in which one or more tumors form in your pancreas or the upper part of your small intestine (duodenum). Market Analysis and Insights: Global Zollinger - Ellison Syndrome Testing Market The global Zollinger - Ellison Syndrome Testing market size is proj…
- 世界の多嚢胞性卵巣症候群治療市場規模・現状・予測（2021年-2027年） Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velv…